Wockhardt Limited (NSE:WOCKPHARMA)
India · Delayed Price · Currency is INR 2,062.50
+27.90 (1.37%)
Nov 12, 2026, 3:30 PM IST
Wockhardt Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 37,510 | 33,730 | 30,120 | 27,980 | 26,510 | 32,300 |
Other Revenue | 890 | 890 | 300 | 320 | 60 | - |
| 38,400 | 34,620 | 30,420 | 28,300 | 26,570 | 32,300 | |
Revenue Growth | 27.70% | 13.81% | 7.49% | 6.51% | -17.74% | 19.28% |
Cost of Revenue | 13,810 | 12,170 | 12,090 | 12,320 | 11,720 | 13,490 |
Gross Profit | 24,590 | 22,450 | 18,330 | 15,980 | 14,850 | 18,810 |
Selling, General & Admin | 7,753 | 7,283 | 6,534 | 6,298 | 6,380 | 7,509 |
Other Operating Expenses | 8,737 | 7,977 | 7,526 | 7,662 | 7,390 | 8,321 |
Operating Expenses | 18,770 | 17,530 | 16,230 | 16,190 | 16,280 | 18,300 |
Operating Income | 5,820 | 4,920 | 2,100 | -210 | -1,430 | 510 |
Interest Expense | -2,130 | -2,080 | -2,510 | -2,910 | -2,920 | -2,820 |
Interest & Investment Income | 70 | 70 | 90 | 60 | 40 | 60 |
Currency Exchange Gain (Loss) | 460 | 220 | -41.4 | 18.6 | 796 | 108.6 |
Other Non Operating Income (Expenses) | -40 | -50 | -28.6 | -138.6 | -96 | -158.6 |
EBT Excluding Unusual Items | 4,180 | 3,080 | -390 | -3,180 | -3,610 | -2,300 |
Merger & Restructuring Charges | - | - | - | - | -130 | - |
Gain (Loss) on Sale of Assets | - | - | - | -1,310 | 280 | - |
Asset Writedown | - | - | - | -140 | - | - |
Other Unusual Items | 270 | -700 | 230 | 430 | -2,780 | -1,810 |
Pretax Income | 4,450 | 2,380 | -160 | -4,200 | -6,240 | -4,110 |
Income Tax Expense | 400 | 390 | 410 | 520 | -30 | -1,320 |
Earnings From Continuing Operations | 4,050 | 1,990 | -570 | -4,720 | -6,210 | -2,790 |
Net Income to Company | 4,050 | 1,990 | -570 | -4,720 | -6,210 | -2,790 |
Minority Interest in Earnings | 50 | 140 | 100 | 90 | 620 | 350 |
Net Income | 4,100 | 2,130 | -470 | -4,630 | -5,590 | -2,440 |
Net Income to Common | 4,100 | 2,130 | -470 | -4,630 | -5,590 | -2,440 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 160 | 162 | 157 | 144 | 144 | 121 |
Shares Outstanding (Diluted) | 161 | 163 | 157 | 144 | 144 | 121 |
Shares Change | -3.22% | 3.66% | 8.77% | 0.13% | 19.50% | 0.35% |
EPS (Basic) | 25.59 | 13.11 | -3.00 | -32.10 | -38.80 | -20.24 |
EPS (Diluted) | 25.55 | 13.10 | -3.02 | -32.10 | -38.80 | -20.24 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | 2,890 | 2,540 | -1,160 | 1,600 | 1,110 | 2,950 |
Free Cash Flow Per Share | 18.00 | 15.62 | -7.39 | 11.09 | 7.71 | 24.47 |
Gross Margin | 64.04% | 64.85% | 60.26% | 56.47% | 55.89% | 58.24% |
Operating Margin | 15.16% | 14.21% | 6.90% | -0.74% | -5.38% | 1.58% |
Profit Margin | 10.68% | 6.15% | -1.54% | -16.36% | -21.04% | -7.55% |
Free Cash Flow Margin | 7.53% | 7.34% | -3.81% | 5.65% | 4.18% | 9.13% |
EBITDA | 7,490 | 6,580 | 3,670 | 1,380 | 420 | 2,260 |
EBITDA Margin | 19.50% | 19.01% | 12.06% | 4.88% | 1.58% | 7.00% |
D&A For EBITDA | 1,670 | 1,660 | 1,570 | 1,590 | 1,850 | 1,750 |
EBIT | 5,820 | 4,920 | 2,100 | -210 | -1,430 | 510 |
EBIT Margin | 15.16% | 14.21% | 6.90% | -0.74% | -5.38% | 1.58% |
Effective Tax Rate | 8.99% | 16.39% | - | - | - | - |
Revenue as Reported | 38,630 | 34,840 | 30,740 | 28,810 | 27,730 | 32,500 |